60. Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities.; Balasubramaniam P, Stevenson O, Berth-Jones J.; Br J Dermatol. 2004 Apr;150(4):741-6.
59. [Successful treatment of sarcoidosis with cutaneous and pulmonary involvement with fumaric acid ester]; Gutzmer R, Kapp A, Werfel T.; Hautarzt. 2004 Jun;55(6):553-7. German.
58. Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses.; Litjens NH, Rademaker M, Ravensbergen B, Rea D, van der Plas MJ, Thio B, Walding A, van Dissel JT, Nibbering PH.; Eur J Immunol. 2004 Feb;34(2):565-75.
57. Fumaric acid esters in the treatment of psoriasis: an Italian experience.; Carboni I, De Felice C, De Simoni I, Soda R, Chimenti S.; J Dermatolog Treat. 2004 Jan;15(1):23-6.
56. Dimethylfumarate is a potent inducer of apoptosis in human T cells.; Treumer F, Zhu K, Glaser R, Mrowietz U.; J Invest Dermatol. 2003 Dec;121(6):1383-8.
55. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis; Hoefnagel J.J., Thio H.B., Willemze R., Bouwes Bavninck J.N.; Br. J. Dermatol. 2003, 149, 363-369
54. Efficacy of fumaric acid ester monotherapy in psoriasis pustulosa palmoplantaris; Ständer H., Stadelmann A., Luger T., Traupe H.; Br. J. Dermatol. 2003, 149, 220-222
53. Zulassungsrelevante klinische Studie; Roszkiewicz J., Baran E., Placek W., Langner A.; personal communication, 2003
52. Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines; Litjens N.H., Nibbering P.H., Barrois A.J., Zomerdijk T.P.,Van Den Oudenrijn A.C., Noz K.C., Rademaker M., Van De Meide P.H., Van Dissel J.T., Thio B.; Br. J. Dermatol. 2003, 148, 444-451
51. Dimethylfumarate Inhibits TNF-Induced Nuclear Entry of NF-kappa B/p65 in Human Endothelial Cells; Loewe R., Holnthoner W., Gröger M., Pillinger M., Gruber F., Mechtcheriakova D.,Hofer E., Wolff K., Petzelbauer P.; J. Immunol. 2002, 168, 4781-4787
50. Fumaric acid esters are potent immunosuppressants: inhibition of acute and chronic rejection in rat kidney transplantation models by methyl hydrogen fumarate; Lehmann M., Risch K., Nizze H., Lutz J., Heemann U., Volk H.D., Asadullah K.; Arch. Dermatol. Res. 2002 Dec, 294(9), 399-404
49. Treatment of disseminated granuloma annulare with fumaric acid esters; Kreuter A., Gambichler T., Altmeyer P., Brockmeyer N.H.; BMC Dermatol. 2002 Mar, 2(1), 5
48. Successful therapy of annular elastolytic giant cell granuloma with fumaric Acid esters.; Gutzmer R., Breuer K., Kiehl P., Kapp A., Werfel T.; Dermatology 2002, 205(4), 421-424 
47. Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris; Gollnick H.,Altmeyer P., Kaufmann R., Ring J., Christophers E., Pavel S., Ziegler J.; Dermatology 2002, 205(1), 46-53
46. Inhibition of Dendritic Cell Differentiation by Fumaric Acid Esters; Zhu K., Mrowietz U.; J. Invest. Dermatol. 2001, 116(2), 203-208
45. The antipsoriatic drug dimethylfumarate strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cells; Stoof T.J., Flier J., Sampat S., Nierboer C., Tensen C.P., Boorsma D.M.; Br. J. Dermatol 2001, 144, 1114-1120
44. Granuloma anulare disseminatum – erfolgreiche Therapie mit Fumarsäureester; Schulze-Dirks A., Petzoldt D.; Hautarzt 2001, 52, 228-230  
43. Methyl Hydrogen Fumarate Inhibits Acute and Chronic Rejection in Rat Kidney Transplantation Models; Risch K., Strebel H.P., Joshi R.K., Lutz J., Brock J., Asadullah K., Volk H.D.,Lehmann M.; Transplant Proc 2001, 33, 545-546
42. Immunmodulation durch Fumaderm® plus MTX; Radenhausen M., Altmeyer P.; Symposium Medical 2001, 12, 37-38  
41. Dimethylfumarate Inhibits Tumor-Necrosis-Factor-Induced CD62E Expression in an NF-kB-Dependent Manner; Loewe R., Pillinger M., de Martin R., Mrowietz U., Gröger M., Holnthoner W., Wolff K., Wiegrebe W., Jirovsky D., Petzelbauer P.; J. Invest. Dermatol. 2001, 117, 1363-1368 
40. Systemtherapie mit Fumarsäureestern; Jansen T., Hoffmann M., Altmeyer P.; hautnah dermatologie 2001, 2, 46-51  
39. Addition of Pentoxifylline Could Reduce the Side Effects of FumaricAcid Esters in the Treatment of Psoriasis; Friedrich M., Sterry W., Klein A., Rückert R., Döcke W.D., Asadullah K.; Acta. Derm. Venereol. 2001, 81, 429-430
38. Dithranol and Dimethylfumarate Suppress the Interferon-gamma-Induced Up-Regulation of Cytokeratin 17 as a Putative Psoriasis Autoantigen in vitro; Bonnekoh B., Böckelmann R.,Ambach A., Gollnick H.; Skin. Pharmacol. Appl. Skin. Physiol. 2001, 14, 217-225
37. A systematic review of treatments for severe psoriasis; Griffiths C.E.M., Clark C.M., Chalmers R.J.G., Li Wan Po A., Williams H.C.; Health Technol. Assess. 2000, 4(40), 76-79
36. Dimethylfumarat ist unter den Fumaderm®-Inhaltsstoffen der stärkste Induktor von Apoptose-Phänomenen in lympho-histiozytären U-937-Zellen; Sebök B., Mahrle G., Gollnick H., Bonnekoh B.; Z. Hautkr. 2000, (75), 1-5  
35. Stimulation von T Lymphozyten in Gegenwart von Monomethylfumarat (MMF) oder Tacalcitol induziert antientzündliche Mediatoren; Viale O., Mailhammer R., Röcken M; Hautarzt1999, 50, Supplement 1, 154
34. Fumaric acid derivates in psoriatic arthritis; Möhrenschlager M., Vogt H.J., Engst R., Ring J.; Brit. J. Dermatol. 1999, 141, 993-994  
33. Immunmodulierende Therapie bei Psoriasis vulgaris; Christ H.W.; Med. Klin. 1999, 94, Suppl III, 90-92
32. Fumaric acid esters: an alternative systemic treatment for psoriasis; Ameen M., Russell-Jones R.; Clin. Exp. Dermatol. 1999 Sep, 24(5), 361-364
31. Leitlinien zur Therapie mit Fumarsäureestern; Altmeyer P., Bieber T., Christophers E., Goos M., Mrowietz U., Röcken M., Schopf R.E., Schöpf E., Sterry W.; Brit. J. Dermatol. 1999, 141, 424-429
30. The antipsoriatic dimethyl-fumarate suppresses interferon-gamma-induced ICAM-1 and HLA-DR expression on hyperproliferative keratinocytes. Quantification by a culture plate-directed APAAP-ELISA technique; Sebok B., Bonnekoh B., Vetter R., Schneider I., Gollnick H., Mahrle G.; Eur. J. Dermatol. 1998 Jan-Feb, 8(1), 29-32
29. The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network; Ockenfels H.M., Schultewolter T.,Ockenfels G., Funk R., Goos M.; Br. J. Dermatol. 1998 Sep, 139(3), 390-395
28. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study; Mrowietz U., Christophers E., Altmeyer P.; Br. J. Dermatol. 1998 Mar, 138(3), 456-460
27. Fumaric Acid Esters Suppress Peripheral CD4- and CD8-Positive Lymphocytes in Psoriasis; Höxtermann S., Nüchel C., Altmeyer P.; Dermatology 1998, 196, 223-230
26. Sarkoidose mit kutaner Dissemination: zwei Fälle unter Fumarsäuretherapie; Dümmler U., Rinke M., Sabel R., Gollnick H.; Allergologie 1998, 21, 387  
25. Nephrotoxische Wirkungen durch Fumarsäure-Derivate in der Behandlung der Psoriasis vulgaris; Boesken W.H., Oser B., Roth J., Wedekind S., Wokalek H.; Nieren- und Hochdruckkrankheiten 1998, 27, 145-150
24. Intracellular signalling by binding sites for the antipsoriatic agent monomethylfumarate on human granulocytes; Nibbering P.H., Thio B., Bezemer A.C., Beijersbergen R.L., Zomerdijk T.P.L. Br. J. Dermatol. 1997, 137, 65-75
23. Narbensarkoidose nach Akupunktur - erfolgreiche Behandlung mit Fumarsäureestern; Jahn S., Röchling A., Altmeyer P.; Allergologie 1997, 20 (8), 423-424 
22. Influence of monomethylfumarate on monocytic cytokine formation - explanation for adverse and therapeutic effects in psoriasis?; Asadullah K., Schmid H., Friedrich M., Randow F., Volk H.D., Sterry W., Döcke W.D.; Arch. Dermatol. Res. 1997 Oct, 289 (11), 623-630
21. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate; de Jong R., Bezemer A.C., Zomerdijk T.P.L., van de Pouw-Kraan T., Ottenhoff T.H.M.,Nibbering P.H.; Eur. J. Immunol.1996, 26, 2067-2074
20. Systemtherapie der Psoriasis; Altmeyer P., Nüchel C.; Dtsch. Med. Wschr. 1996, 121, 1605-1607  
19. Verlaufsbeobachtungen der Lymphozytensubpopulationen bei Psoriasis-Patienten unter oraler Therapie mit Fumaraten; Altmeyer P., Höxtermann S., Auer T.; Akt. Dermatol. 1996, 22,272-277
18. Das Wirkungs- und Sicherheitsprofil von Fumarsäureestern in der oralen Langzeittherapie bei schwerer therapieresistenter Psoriasis vulgaris; Altmeyer P., Hartwig R., Matthes U.; Hautarzt 1996, 47, 190-196
17. Long-term systemic therapy with dimethylfumarate and monoethylfumarate (Fumaderm®) in psoriasis; Thio H.B., van der Schroeff J.G., Nugteren-Huying W.M., Vermeer B.J..; J. Eur. Acad. Dermatol. Venerol. 1995, 4, 35-40
16. Non-invasive assessment of the antipsoriatic activity of fumaric acid derivates; Hoffmann K., Dirschka Th., Schwarze H., Stücker M., Matthes U., el-Gammal S., Hoffmann A., Altmeyer P.; Skin Res. Tech. 1995, 1, 145-151  
15. Antiproliferative and cytotoxic profiles of antipsoriatic fumaric acid derivates in keratinocyte cultures; Sebök B., Bonnekoh B., Geisel J., Mahrle G.; Eur. J. Pharmacol. 1994,270, 79-87
14. IL-1 Alpha Induced Expression of ICAM-1 on Cultured Hyperproliferative Keratinocytes: Suppression by Antipsoriatic Dimethyl-Fumarate; Sebök B., Bonnekoh B., Mahrle G.; Int. J. Dermatol. 1994, 33 (5), 367-370
13. Fumaric acid derivates evoke a transient increase in intracellular free calcium concentration and inhibit the proliferation of human keratinocytes; Thio H.B., Zomerdijk T.P.L., Oudshoorn C., Kempenaar J., Nibbering P.H., van der Schroeff J.G., Ponec M.; Br. J. Dermatol. 1994, 131, 856-861
12. Fumaric Acid Esters (FAEs) Suppress CD 15- and ODP 4-positive Cells in Psoriasis; Bacharach-Buhles M., Pawlak F.M., Matthes U., Joshi R.K., Altmeyer P.; Acta. Derm. Venereol. (Stockh) 1994, Suppl. 186, 79-82
11. Antipsoriatic effect of fumaric acid derivates. Results of a multicenter double-blind study in 100 patients; Altmeyer P.J., Matthes U., Pawlak F., Hoffmann K., Frosch P.J., Ruppert P., Wassilew S.W., Horn T., Kreysel H.W., Lutz G., Barth J., Rietzschel I., Joshi R.K.; J. Am. Acad. Dermatol. 1994, 30, 977-981
10. Behandlung einer therapieresistenten Psoriasis pustulosa generalisata mit Fumarsäureestern; Pawlak F.M., Matthes U., Bacharach-Buhles M., Altmeyer P.; Akt. Dermatol. 1993, 19, 6-8  
9. Effects of Monomethylfumarate on Human Granulocytes; Nibbering P.H., Thio B., Zomerdijk T.P.L., Bezemer A.C., Beijersbergen R.L., van Furth R.; J. Invest. Dermatol. 1993, 101, 37-42
8. Fumarsäuremonoäthylester: Zeit- und konzentrationsabhängige Inhibition der Nukleinsäuresynthese in vitro; Rompel R., Kraft F., Petres J.; Akt. Dermatol. 1992, 18, 309-311  
7. Fumaric Acid Therapy for Psoriatic Arthritis. A Randomized, Double-blind, Placebo-controlled Study; Peeters A.J. , Dijkmans B.A.C., van der Schroeff J.G.; Br. J. of Rheumatol. 1992, 31 (7), 502-504
6. Fumaric acid therapy in psoriasis: Results and side effects of 2 years of treatment; Kolbach D.N., Nieboer C.; J. Am. Acad. Dermatol. 1992, 27, 769-771
5. Fumaric acid therapy for psoriasis: A randomized, double-blind, placebo-controlled study; Nugteren-Huying W.M., van der Schroeff J.G., Hermans J., Suurmond D., J. Am. Acad. Dermatol. 1990, 22, 311-312
4. Fumaric Acid Therapy in Psoriasis: A Double-Blind Comparison between Fumaric Acid Compound Therapy and Monotherapy with Dimethylfumaric Acid Ester; Nieboer C., de Hoop D., Langendijk P.N.J., van Loenen A.C., Gubbels J.; Dermatologica 1990, 181, 33-37
3. Erfolgreiche Fumarsäurebehandlung bei therapieresistenter Psoriasis; Klein E.F., Fritz K.; Dt. Derm. 1990, 38, 7
2. Systemic therapy with fumaric acid derivates: New possibilities in the treatment of psoriasis; Nieboer C., de Hoop D., van Loenen A.C., Langendijk P.N.J., van Dijk E.; J. Am. Acad. Dermatol. 1989, 20, 601-608
1. Perorale Langzeitbehandlung der Psoriasis mit Fumarsäurederivaten; Bayard W., Hunziker T., Krebs A., Speiser P., Joshi R.; Hautarzt 1987, 38, 279-285 
© schuppenflechte.info-All rights reserved-Last update: